Pub Date : 2023-11-23eCollection Date: 2023-11-01DOI: 10.3892/mi.2023.124
Dimitrios Sfairopoulos, Christos S Konstantinou, Panagiotis Korantzopoulos
In clinical practice, the accurate diagnosis of the causes of syncope is often challenging and demanding. Moreover, certain rare electrocardiographic phenomena may complicate the diagnostic workup, leading to imprecise diagnoses. The present study briefly describes the case of an 82-year-old male patient with ischemic cardiomyopathy who suffered syncopal episodes in the setting of trifascicular block. The 12-lead electrocardiogram revealed premature ventricular contractions and non-conducted P waves due to the phenomenon of retrograde concealed conduction. Following the exclusion of myocardial ischemia, an electrophysiological study yielded abnormal results and a biventricular pacemaker was implanted. Although retrograde concealed conduction is considered a benign phenomenon caused by the transient modification of antegrade atrioventricular conduction characteristics, further meticulous investigation is required in patients with concomitant baseline conduction abnormalities and/or structural heart disease.
在临床实践中,准确诊断晕厥的原因往往具有挑战性,要求很高。此外,某些罕见的心电图现象可能会使诊断工作复杂化,导致诊断不精确。本研究简要描述了一例 82 岁男性缺血性心肌病患者在三束支传导阻滞的情况下发生晕厥的病例。12 导联心电图显示,由于逆行隐匿传导现象,患者出现室性早搏和非传导性 P 波。在排除心肌缺血后,电生理检查结果异常,于是植入了双心室起搏器。虽然逆行隐匿性传导被认为是一种良性现象,是由逆行房室传导特性的短暂改变引起的,但对于同时伴有基线传导异常和/或结构性心脏病的患者,需要进行进一步的细致检查。
{"title":"Syncope in the setting of trifascicular block and retrograde concealed conduction: A case report.","authors":"Dimitrios Sfairopoulos, Christos S Konstantinou, Panagiotis Korantzopoulos","doi":"10.3892/mi.2023.124","DOIUrl":"https://doi.org/10.3892/mi.2023.124","url":null,"abstract":"<p><p>In clinical practice, the accurate diagnosis of the causes of syncope is often challenging and demanding. Moreover, certain rare electrocardiographic phenomena may complicate the diagnostic workup, leading to imprecise diagnoses. The present study briefly describes the case of an 82-year-old male patient with ischemic cardiomyopathy who suffered syncopal episodes in the setting of trifascicular block. The 12-lead electrocardiogram revealed premature ventricular contractions and non-conducted P waves due to the phenomenon of retrograde concealed conduction. Following the exclusion of myocardial ischemia, an electrophysiological study yielded abnormal results and a biventricular pacemaker was implanted. Although retrograde concealed conduction is considered a benign phenomenon caused by the transient modification of antegrade atrioventricular conduction characteristics, further meticulous investigation is required in patients with concomitant baseline conduction abnormalities and/or structural heart disease.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"64"},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ameloblastic fibro-odontoma (AFO) is a rare, slow-growing neoplastic lesion classified as a benign, epithelial odontogenic mesenchymal tumor. This tumor exhibits histological features characteristic of both ameloblastic fibromas and complex odontomas. The clinical manifestation of AFO is typically characterized by the asymptomatic enlargement of the jawbones. Radiographically, it presents as a distinct radiolucent region, indicating the presence of radiopaque substances with varying degrees of irregularities in size and morphology. Standard therapeutic intervention involves enucleation. Despite its benign nature, AFO can cause significant morbidity if left untreated. Therefore, prompt diagnosis and appropriate management are essential to ensure optimal patient outcomes. The present study describes the case (clinical presentation and management) of an 18-year-old male patient with an AFO lesion located in the posterior mandible. This particular case was treated with conservative measures involving surgical enucleation along with the extraction of the impacted tooth and the curettage of residual bone.
绒毛状纤维牙瘤(AFO)是一种罕见的、生长缓慢的肿瘤性病变,属于良性、上皮性牙本质间充质肿瘤。这种肿瘤在组织学上具有绒毛状纤维瘤和复合牙瘤的特征。AFO 的临床表现以无症状的颌骨增大为典型特征。在影像学上,它表现为一个明显的放射状区域,表明存在不透射线的物质,其大小和形态存在不同程度的不规则。标准的治疗干预包括去核手术。尽管 AFO 是良性的,但如果不及时治疗,会导致严重的发病率。因此,及时诊断和适当治疗对确保患者获得最佳治疗效果至关重要。本研究描述了一名 18 岁男性患者的病例(临床表现和治疗),他的 AFO 病变位于下颌骨后部。对该病例采取了保守治疗措施,包括手术去核、拔除受撞击的牙齿和刮除残留骨质。
{"title":"Ameloblastic fibro‑odontoma in the posterior mandible: A case report.","authors":"Mahima Goel, Ali Qamar, Mimansa Daftary, Sujata Rajesh Chhabile, Shruti Pundkar, Manish Sharma","doi":"10.3892/mi.2023.123","DOIUrl":"https://doi.org/10.3892/mi.2023.123","url":null,"abstract":"<p><p>Ameloblastic fibro-odontoma (AFO) is a rare, slow-growing neoplastic lesion classified as a benign, epithelial odontogenic mesenchymal tumor. This tumor exhibits histological features characteristic of both ameloblastic fibromas and complex odontomas. The clinical manifestation of AFO is typically characterized by the asymptomatic enlargement of the jawbones. Radiographically, it presents as a distinct radiolucent region, indicating the presence of radiopaque substances with varying degrees of irregularities in size and morphology. Standard therapeutic intervention involves enucleation. Despite its benign nature, AFO can cause significant morbidity if left untreated. Therefore, prompt diagnosis and appropriate management are essential to ensure optimal patient outcomes. The present study describes the case (clinical presentation and management) of an 18-year-old male patient with an AFO lesion located in the posterior mandible. This particular case was treated with conservative measures involving surgical enucleation along with the extraction of the impacted tooth and the curettage of residual bone.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"63"},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10704407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Corrigendum] Stormorken syndrome caused by STIM1 mutation: A case report and literature review","authors":"Wenqiang Sun, Jinhui Hu, Mengzhao Li, Xueping Zhu","doi":"10.3892/mi.2023.122","DOIUrl":"https://doi.org/10.3892/mi.2023.122","url":null,"abstract":"","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"171 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139257399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Nana, Konstantinos Spanos, G. Kouvelos, V. Georgakopoulou, Ioannis G. Lempesis, N. Trakas, P. Sklapani, Konstantinos Paterakis, George Fotakopoulos, Alexandros Brotis
{"title":"Carotid artery stenting and endarterectomy surgery techniques: A 30‑year time‑lapse","authors":"P. Nana, Konstantinos Spanos, G. Kouvelos, V. Georgakopoulou, Ioannis G. Lempesis, N. Trakas, P. Sklapani, Konstantinos Paterakis, George Fotakopoulos, Alexandros Brotis","doi":"10.3892/mi.2023.121","DOIUrl":"https://doi.org/10.3892/mi.2023.121","url":null,"abstract":"","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"9 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139267982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saman Fakhralddin, Rawa Ali, Ari Abdullah, Farman Faraj, Dlsoz Hussein, Shvan Mohammed, Berun Abdalla, Fahmi Kakamad, Hawbash Rahim
Pleomorphic giant cell carcinoma (PGCC) is an exceptionally uncommon form of prostate adenocarcinoma. It consists of unusually large and irregular cells with varied nuclei. The present study describes a rare case of prostatic PGCC. A 65‑year‑old male patient presented to the urology clinic with severe dysuria, nocturia, and frequent, urgent, and difficult urination for a period of 3 months. Pelvic magnetic resonance imaging revealed a large pelvic mass. A prostate biopsy was performed, and immunohistochemical analysis revealed positivity for the pan‑epithelial markers, AE1/AE3, alpha‑methyl acyl‑CoA racemase, and focally for sphingolipid activator protein‑2. While waiting for his pathology report, the patient's condition deteriorated, and he was diagnosed with intestinal obstruction. The patient underwent laparotomy and end colostomy. Later, he developed severe sepsis and wound dehiscence. After 2 weeks, the patient succumbed due to multiorgan failure. Prostatic PGCC cases are frequently associated with previous chemo‑, hormone, or radiation therapy. Prior to the diagnosis of PGCC, it is critical to rule out urothelial carcinoma. Early recognition of this rare condition can lead to more effective therapy. Prostatic PGCC is extremely rare. Immunohistochemistry for prostatic markers, such as prostate‑specific membrane antigen, prostate‑specific antigen, NK3 homeobox 1 and androgen receptor, can be used to confirm its origin.
{"title":"Pleomorphic giant cell carcinoma of the prostate: A case report and mini‑review of the literature","authors":"Saman Fakhralddin, Rawa Ali, Ari Abdullah, Farman Faraj, Dlsoz Hussein, Shvan Mohammed, Berun Abdalla, Fahmi Kakamad, Hawbash Rahim","doi":"10.3892/mi.2023.120","DOIUrl":"https://doi.org/10.3892/mi.2023.120","url":null,"abstract":"Pleomorphic giant cell carcinoma (PGCC) is an exceptionally uncommon form of prostate adenocarcinoma. It consists of unusually large and irregular cells with varied nuclei. The present study describes a rare case of prostatic PGCC. A 65‑year‑old male patient presented to the urology clinic with severe dysuria, nocturia, and frequent, urgent, and difficult urination for a period of 3 months. Pelvic magnetic resonance imaging revealed a large pelvic mass. A prostate biopsy was performed, and immunohistochemical analysis revealed positivity for the pan‑epithelial markers, AE1/AE3, alpha‑methyl acyl‑CoA racemase, and focally for sphingolipid activator protein‑2. While waiting for his pathology report, the patient's condition deteriorated, and he was diagnosed with intestinal obstruction. The patient underwent laparotomy and end colostomy. Later, he developed severe sepsis and wound dehiscence. After 2 weeks, the patient succumbed due to multiorgan failure. Prostatic PGCC cases are frequently associated with previous chemo‑, hormone, or radiation therapy. Prior to the diagnosis of PGCC, it is critical to rule out urothelial carcinoma. Early recognition of this rare condition can lead to more effective therapy. Prostatic PGCC is extremely rare. Immunohistochemistry for prostatic markers, such as prostate‑specific membrane antigen, prostate‑specific antigen, NK3 homeobox 1 and androgen receptor, can be used to confirm its origin.","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135091746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-31eCollection Date: 2023-11-01DOI: 10.3892/mi.2023.119
Qiang Ma, Jin Bao, Naiying Sun, Xingjie Yang, Li Liu, Ying Chen, Wenjun Guo, Lixiang Gao
The present study aimed to investigate the expression of ubiquitin-conjugating enzyme E2 variant 1 (Ube2v1) in colorectal cancer (CRC) and its clinical significance. The differential expression of Ube2v1 in CRC tissues and normal intestinal tissues, as well as the association between Ube2v1 expression and the prognosis of patients with CRC were analyzed using bioinformatics analyses. TIMER database analysis revealed higher Ube2v1 expression in CRC tissues than in normal intestinal tissues. Cancerous and normal tissues collected retrospectively from 37 cases of CRC between July, 2022 and June, 2023 were analyzed for Ube2v1 expression using immunohistochemistry, and the associations between Ube2v1 expression and the clinical pathological features of patients with CRC were analyzed. Ube2v1 expression was associated with lymph node metastasis in patients with CRC (P<0.05). However, bioinformatics analysis using the GEPIA2 and HPA database revealed that Ube2v1 was not associated with the overall survival of patients with CRC. On the whole, the present study demonstrates that due to its high expression and association with lymph node metastasis, Ube2v1 may serve as a potential target for the treatment of CRC.
{"title":"Clinicopathological significance and prognostic implications of Ube2v1 expression in colorectal cancer.","authors":"Qiang Ma, Jin Bao, Naiying Sun, Xingjie Yang, Li Liu, Ying Chen, Wenjun Guo, Lixiang Gao","doi":"10.3892/mi.2023.119","DOIUrl":"10.3892/mi.2023.119","url":null,"abstract":"<p><p>The present study aimed to investigate the expression of ubiquitin-conjugating enzyme E2 variant 1 (Ube2v1) in colorectal cancer (CRC) and its clinical significance. The differential expression of Ube2v1 in CRC tissues and normal intestinal tissues, as well as the association between Ube2v1 expression and the prognosis of patients with CRC were analyzed using bioinformatics analyses. TIMER database analysis revealed higher Ube2v1 expression in CRC tissues than in normal intestinal tissues. Cancerous and normal tissues collected retrospectively from 37 cases of CRC between July, 2022 and June, 2023 were analyzed for Ube2v1 expression using immunohistochemistry, and the associations between Ube2v1 expression and the clinical pathological features of patients with CRC were analyzed. Ube2v1 expression was associated with lymph node metastasis in patients with CRC (P<0.05). However, bioinformatics analysis using the GEPIA2 and HPA database revealed that Ube2v1 was not associated with the overall survival of patients with CRC. On the whole, the present study demonstrates that due to its high expression and association with lymph node metastasis, Ube2v1 may serve as a potential target for the treatment of CRC.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-30eCollection Date: 2023-11-01DOI: 10.3892/mi.2023.118
Jing-Yu Wang, Shu-Lan Yao, Xin-Yi Hou, Hai-Lu Xiao, Bin Lu
The current strategies for the treatment of vitiligo using phototherapy usually involve treatment for two-three times per week; however, in practice, the number of patient sessions does not meet this standard. The present study found that phototherapy once a week was also effective. The present study was designed to examine the efficacy of weekly light therapy. For this purpose, 296 patients with vitiligo were included and divided into five sub-samples of the neck, face, trunk, extremities and scalp according to the site of phototherapy, and were treated once or twice weekly with phototherapy. The difference in efficacy between phototherapy performed once and twice weekly was observed using a Chi-squared test. It was concluded that there was a minimal difference between phototherapy performed twice weekly compared to once weekly for the treatment of vitiligo on the face, neck, torso, limbs and scalp. Thus, phototherapy once a week is valid for the treatment of vitiligo, although weekly light therapy takes longer to restore color for the first time.
{"title":"Weekly phototherapy is an effective therapy for patients with vitiligo.","authors":"Jing-Yu Wang, Shu-Lan Yao, Xin-Yi Hou, Hai-Lu Xiao, Bin Lu","doi":"10.3892/mi.2023.118","DOIUrl":"10.3892/mi.2023.118","url":null,"abstract":"<p><p>The current strategies for the treatment of vitiligo using phototherapy usually involve treatment for two-three times per week; however, in practice, the number of patient sessions does not meet this standard. The present study found that phototherapy once a week was also effective. The present study was designed to examine the efficacy of weekly light therapy. For this purpose, 296 patients with vitiligo were included and divided into five sub-samples of the neck, face, trunk, extremities and scalp according to the site of phototherapy, and were treated once or twice weekly with phototherapy. The difference in efficacy between phototherapy performed once and twice weekly was observed using a Chi-squared test. It was concluded that there was a minimal difference between phototherapy performed twice weekly compared to once weekly for the treatment of vitiligo on the face, neck, torso, limbs and scalp. Thus, phototherapy once a week is valid for the treatment of vitiligo, although weekly light therapy takes longer to restore color for the first time.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89720998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lung cancer is a common malignancy that has usually already metastasized at the time of diagnosis; however, thyroid metastases are extremely rare. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion has been observed in 3-7% of cases of lung adenocarcinoma. ALK inhibitor therapy has been shown to exert a positive effect on disease progression. The present study describes the case of a patient with ALK-positive non-small cell lung carcinoma and thyroid metastases who exhibited a minimal response to ALK inhibitor therapy in the primary lesion, but had a complete pathological response in the thyroid, as confirmed by a thyroid biopsy. The present case report undermines the need for further evidence from genomic testing following this different tumor course in thyroid tissue.
{"title":"Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report.","authors":"Ertugrul Bayram, Tugba Toyran, Burak Güney, Aysun Hatice Uguz, Derya Gümürdülü, Semra Paydas","doi":"10.3892/mi.2023.117","DOIUrl":"https://doi.org/10.3892/mi.2023.117","url":null,"abstract":"<p><p>Lung cancer is a common malignancy that has usually already metastasized at the time of diagnosis; however, thyroid metastases are extremely rare. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) fusion has been observed in 3-7% of cases of lung adenocarcinoma. ALK inhibitor therapy has been shown to exert a positive effect on disease progression. The present study describes the case of a patient with ALK-positive non-small cell lung carcinoma and thyroid metastases who exhibited a minimal response to ALK inhibitor therapy in the primary lesion, but had a complete pathological response in the thyroid, as confirmed by a thyroid biopsy. The present case report undermines the need for further evidence from genomic testing following this different tumor course in thyroid tissue.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"57"},"PeriodicalIF":0.0,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-06eCollection Date: 2023-11-01DOI: 10.3892/mi.2023.116
Sherry S Abraham, Geetha Narayanan, Sugeeth Mangalapilly Thambi, Jayasudha Arundhathi Vasudevan, Deepa Susan Joy Philip, Prakash N Purushothaman, Sreejith G Nair, Rekha Nair
Castleman disease (CD) describes a group of rare heterogeneous lymphoproliferative disorders characterized by enlarged hyperplastic lymph nodes. It is classified into unicentric CD (UCD) and multicentric CD (MCD). The present retrospective study examined the data of 11 patients with CD diagnosed and treated at a tertiary cancer center from 2017 to 2022. The median age of the study group was 41 years (range, 24 to 68 years). There were 8 males and 3 females. In total, 7 patients were diagnosed with UCD and 4 patients with MCD. The hyaline-vascular variant was the most common histology in both UCD and MCD. Among the 7 patients with UCD, 5 patients underwent excision, 1 patient underwent debulking followed by radiotherapy and 1 patient received single agent rituximab. Of the patients with UCD, 6 had a complete response (CR) and 1 patient had a partial response (PR). All 4 patients with MCD received systemic treatment, which included single agent rituximab (2 patients), rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (RCHOP) (1 patient) and CHOP (1 patient). Among the patients with MCD, 1 patient attained a CR, 2 patients had a PR and 1 patient succumbed. The 3-year survival rate for the study population was 91%. In summary, CD is a rare disease occurring in immunodeficient patients. UCD is more common and is associated with better outcomes. Surgery is the mainstay of management in UCD whereas MCD requires combination chemotherapy.
{"title":"Castleman disease: Experience from a single institution.","authors":"Sherry S Abraham, Geetha Narayanan, Sugeeth Mangalapilly Thambi, Jayasudha Arundhathi Vasudevan, Deepa Susan Joy Philip, Prakash N Purushothaman, Sreejith G Nair, Rekha Nair","doi":"10.3892/mi.2023.116","DOIUrl":"https://doi.org/10.3892/mi.2023.116","url":null,"abstract":"<p><p>Castleman disease (CD) describes a group of rare heterogeneous lymphoproliferative disorders characterized by enlarged hyperplastic lymph nodes. It is classified into unicentric CD (UCD) and multicentric CD (MCD). The present retrospective study examined the data of 11 patients with CD diagnosed and treated at a tertiary cancer center from 2017 to 2022. The median age of the study group was 41 years (range, 24 to 68 years). There were 8 males and 3 females. In total, 7 patients were diagnosed with UCD and 4 patients with MCD. The hyaline-vascular variant was the most common histology in both UCD and MCD. Among the 7 patients with UCD, 5 patients underwent excision, 1 patient underwent debulking followed by radiotherapy and 1 patient received single agent rituximab. Of the patients with UCD, 6 had a complete response (CR) and 1 patient had a partial response (PR). All 4 patients with MCD received systemic treatment, which included single agent rituximab (2 patients), rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (RCHOP) (1 patient) and CHOP (1 patient). Among the patients with MCD, 1 patient attained a CR, 2 patients had a PR and 1 patient succumbed. The 3-year survival rate for the study population was 91%. In summary, CD is a rare disease occurring in immunodeficient patients. UCD is more common and is associated with better outcomes. Surgery is the mainstay of management in UCD whereas MCD requires combination chemotherapy.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 6","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-03eCollection Date: 2023-09-01DOI: 10.3892/mi.2023.115
Fatih Bal
The present study examined the effectiveness of increasing levels of exposure therapy, which is applied for the treatment of maladaptive behaviors and anxiety. A total of 16 sessions were applied to the study group in the experimental group three times a week for 10 weeks. Patients aged ≥18 years whom the referring clinician evaluated as meeting the criteria for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-V-TR) Generalized Anxiety Disorder were included in the study. For the control group, demographic characteristics and Spielberger's State-Trait Anxiety Inventory were applied in the first session, followed by Spielberger's State-Trait Anxiety Inventory as a post-test and follow-up. Electroencephalography (EEG) recordings of the study group were obtained at the cortical level. Electrodes for EEG measurements were recorded using the International 10/20 Electrode Placement System. EEG data were obtained using the EEG Analysis Program software. Following the data collection phase, all data were entered into cells based on items using SPSS 25 software. When the findings obtained in the study were examined, it was determined that the increasing levels of exposure and behavioral therapy applied for maladaptive anxiety decreased the anxiety levels compared to those before therapy. This finding can be interpreted as that the cortical function-oriented application method for anxiety effectively reduced the anxiety levels of the study group. However, EEG asymmetry revealed a change in the data before and after the application. These findings demonstrate that the application affects the EEG asymmetry changes at the cortical level.
{"title":"Efficacy of increasing levels of exposure therapy in the treatment of maladaptive behaviors and anxiety.","authors":"Fatih Bal","doi":"10.3892/mi.2023.115","DOIUrl":"https://doi.org/10.3892/mi.2023.115","url":null,"abstract":"<p><p>The present study examined the effectiveness of increasing levels of exposure therapy, which is applied for the treatment of maladaptive behaviors and anxiety. A total of 16 sessions were applied to the study group in the experimental group three times a week for 10 weeks. Patients aged ≥18 years whom the referring clinician evaluated as meeting the criteria for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-V-TR) Generalized Anxiety Disorder were included in the study. For the control group, demographic characteristics and Spielberger's State-Trait Anxiety Inventory were applied in the first session, followed by Spielberger's State-Trait Anxiety Inventory as a post-test and follow-up. Electroencephalography (EEG) recordings of the study group were obtained at the cortical level. Electrodes for EEG measurements were recorded using the International 10/20 Electrode Placement System. EEG data were obtained using the EEG Analysis Program software. Following the data collection phase, all data were entered into cells based on items using SPSS 25 software. When the findings obtained in the study were examined, it was determined that the increasing levels of exposure and behavioral therapy applied for maladaptive anxiety decreased the anxiety levels compared to those before therapy. This finding can be interpreted as that the cortical function-oriented application method for anxiety effectively reduced the anxiety levels of the study group. However, EEG asymmetry revealed a change in the data before and after the application. These findings demonstrate that the application affects the EEG asymmetry changes at the cortical level.</p>","PeriodicalId":74161,"journal":{"name":"Medicine international","volume":"3 5","pages":"55"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}